Literature DB >> 19509241

Induction of programmed cell death in ErbB2/HER2-expressing cancer cells by targeted delivery of apoptosis-inducing factor.

Hayat Mahmud1, Benjamin Dälken, Winfried S Wels.   

Abstract

Apoptosis-inducing factor (AIF) is a mitochondrial flavoprotein with NADH oxidase activity that has a vital function in healthy cells but is also an important mediator of caspase-independent programmed cell death in stressed and damaged cells. Here, we generated a truncated AIF derivative (AIF(Delta100)) that lacks the mitochondrial import signal of the protein. Bacterially expressed AIF(Delta100) was functionally active and induced cell death on microinjection into Vero cells accompanied by clear signs of apoptosis. For specific targeting to tumor cells, AIF(Delta100) was genetically fused to the scFv(FRP5) antibody fragment that recognizes the ErbB2 (HER2) receptor tyrosine kinase frequently overexpressed in many human cancers. Recombinant scFv(FRP5)-AIF(Delta100) (5-AIF(Delta100)) protein and a similar scFv(FRP5)-ETA(252-366)-AIF(Delta100) (5-E-AIF(Delta100)) molecule harboring in addition the nontoxic translocation domain of Pseudomonas exotoxin A as an endosome escape function displayed binding to ErbB2-expressing cells followed by protein internalization and accumulation in intracellular vesicles. In the presence of the endosomolytic reagent chloroquine 5-E-AIF(Delta100) but not the similar 5-AIF(Delta100) protein displayed potent cell killing activity, which was strictly dependent on the expression of ErbB2 on the target cell surface. Our results show that recombinant AIF specifically targeted to human cancer cells and delivered into the cytosol has potent cell killing activity, suggesting this molecule as an effector function suitable for the development of humanized immunotoxin-like molecules.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19509241     DOI: 10.1158/1535-7163.MCT-08-1149

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  7 in total

1.  Fusion toxin BLyS-gelonin inhibits growth of malignant human B cell lines in vitro and in vivo.

Authors:  Troy A Luster; Ipsita Mukherjee; Jeffrey A Carrell; Yun Hee Cho; Jeffrey Gill; Lizbeth Kelly; Andy Garcia; Christopher Ward; Luke Oh; Stephen J Ullrich; Thi-Sau Migone; Robin Humphreys
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

2.  Anti-malarial effect of gum arabic.

Authors:  Adil Ballal; Diwakar Bobbala; Syed M Qadri; Michael Föller; Daniela Kempe; Omaima Nasir; Amal Saeed; Florian Lang
Journal:  Malar J       Date:  2011-05-20       Impact factor: 2.979

3.  Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors.

Authors:  Johanna Reul; Janina Frisch; Christine E Engeland; Frederic B Thalheimer; Jessica Hartmann; Guy Ungerechts; Christian J Buchholz
Journal:  Front Oncol       Date:  2019-02-14       Impact factor: 6.244

4.  Identification of Novel Interaction Partners of AIF Protein on the Outer Mitochondrial Membrane.

Authors:  N P Fadeeva; N V Antipova; V O Shender; K S Anufrieva; G A Stepanov; S Bastola; M I Shakhparonov; M S Pavlyukov
Journal:  Acta Naturae       Date:  2018 Oct-Dec       Impact factor: 1.845

5.  EGFR-targeted granzyme B expressed in NK cells enhances natural cytotoxicity and mediates specific killing of tumor cells.

Authors:  Pranav Oberoi; Robert A Jabulowsky; Hayat Bähr-Mahmud; Winfried S Wels
Journal:  PLoS One       Date:  2013-04-03       Impact factor: 3.240

6.  Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer.

Authors:  Nathan Simon; Antonella Antignani; Robert Sarnovsky; Stephen M Hewitt; David FitzGerald
Journal:  J Natl Cancer Inst       Date:  2016-04-13       Impact factor: 11.816

7.  Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells.

Authors:  Maria C Palanca-Wessels; Garrett C Booth; Anthony J Convertine; Brittany B Lundy; Geoffrey Y Berguig; Michael F Press; Patrick S Stayton; Oliver W Press
Journal:  Oncotarget       Date:  2016-02-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.